top of page

April 23, 2024

Response Pharmaceuticals Announces Enrollment of First Patients in a Phase 2 Study Evaluating RDX-002, a Novel Small Molecule iMTP Inhibitor, in Patients Discontinuing GLP-1 Agonists & Clinical Presentation at Obesity Week

August 17, 2023

Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain

Read More

November 21, 2022

Response Pharmaceuticals Closes $8 Million Series A Financing to Fund Clinical Trials for  Patients Suffering from Antipsychotic Induced Weight Gain


Read More

August 17, 2023

Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain

Read More

November 21, 2022

Response Pharmaceuticals Closes $8 Million Series A Financing to Fund Clinical Trials for  Patients Suffering from Antipsychotic Induced Weight Gain


Read More

April 23, 2024

Response Pharmaceuticals Announces Enrollment of First Patients in a Phase 2 Study Evaluating RDX-002, a Novel Small Molecule iMTP Inhibitor, in Patients Discontinuing GLP-1 Agonists & Clinical Presentation at Obesity Week

bottom of page